Cantor Fitzgerald Reaffirms "Overweight" Rating for ALX Oncology (NASDAQ:ALXO)
Cantor Fitzgerald reissued their overweight rating on shares of ALX Oncology (NASDAQ:ALXO – Free Report) in a research note published on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $22.00 price objective on the stock. Separately, Lifesci Capital restated an outperform rating on shares of ALX Oncology in a research report on Wednesday, April […]